Adriamycin pfs and Ototoxicity - a phase IV clinical study of FDA data
Ototoxicity is reported only by a few people who take Adriamycin Pfs.
The phase IV clinical study analyzes which people take Adriamycin pfs and have Ototoxicity. It is created by eHealthMe based on reports of 6,484 people who have side effects while taking Adriamycin pfs from the FDA, and is updated regularly.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
6,484 people reported to have side effects when taking Adriamycin pfs.
Among them, 3 people (0.05%) have Ototoxicity.
What is Adriamycin pfs?
Adriamycin pfs has active ingredients of doxorubicin hydrochloride. eHealthMe is studying from 6,495 Adriamycin pfs users for its effectiveness, alternative drugs and more.
What is Ototoxicity?
Ototoxicity (damage to the ear) is found to be associated with 593 drugs and 325 conditions by eHealthMe.
Number of Adriamycin pfs and Ototoxicity reports submitted per year:
Time on Adriamycin pfs when people have Ototoxicity *:
- < 1 month: 0.0 %
- 1 - 6 months: 100 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Ototoxicity when taking Adriamycin pfs *:
- female: 0.0 %
- male: 100 %
Age of people who have Ototoxicity when taking Adriamycin pfs *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 66.67 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 33.33 %
Common drugs people take besides Adriamycin pfs *:
- Methotrexate: 2 people, 66.67%
- Ifosfamide: 2 people, 66.67%
- Etoposide: 2 people, 66.67%
- Cisplatin: 2 people, 66.67%
- Prednisolone: 1 person, 33.33%
- Oncovin: 1 person, 33.33%
- Fludara: 1 person, 33.33%
- Cyclophosphamide: 1 person, 33.33%
Common side effects people have besides Ototoxicity *:
- Weakness: 1 person, 33.33%
- Numbness And Tingling (unusual prickling sensations): 1 person, 33.33%
- Loss Of Control Of Legs: 1 person, 33.33%
- Difficulty In Walking: 1 person, 33.33%
- Cell Mediated Allergic Reaction (hypersensitivity): 1 person, 33.33%
Common conditions people have *:
- Bone Sarcoma (bone cancer): 2 people, 66.67%
* Approximation only. Some reports may have incomplete information.
Do you take Adriamycin pfs and have Ototoxicity?Check whether Ototoxicity is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Alternative drugs to, pros and cons of Adriamycin pfs:
- Adriamycin pfs (6,495 reports)
Ototoxicity treatments and more:
- Ototoxicity (1,631 reports)
COVID vaccines that are related to Ototoxicity:
- Ototoxicity in Moderna COVID Vaccine
- Ototoxicity in Pfizer BioNTech Covid Vaccine
- Ototoxicity in Johnson and Johnson Covid Vaccine
How severe was Ototoxicity and when was it recovered:
Expand to all the drugs that have ingredients of doxorubicin hydrochloride:
Common drugs associated with Ototoxicity:
All the drugs that are associated with Ototoxicity:
- Ototoxicity (593 drugs)
All the conditions that are associated with Ototoxicity:
- Ototoxicity (325 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on doxorubicin hydrochloride (the active ingredients of Adriamycin pfs) and Adriamycin pfs (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Stivarga and Skin Warm - 2 seconds ago
- Losartan Potassium and Decreased Immune Responsiveness - 5 seconds ago
- Elidel and Kyphosis - 8 seconds ago
- Fludarabine Phosphate and Brain Oedema - 12 seconds ago
- Pravachol and Stable Angina - 12 seconds ago